Irritable Bowel Syndrome clinical trials at UC Health
6 in progress, 4 open to new patients
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
open to eligible people ages 7-17
The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Patients age 7-11 will receive oral liquid or oral solid capsule and patients 12-17 will receive solid oral capsule formulation. Children ages 7-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks. This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of IBS-C.
at UCSF UCSD
OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome
open to eligible people ages 4-65
Study Aims: To analyze stool specimens to test and validate the CalproLab assay against the predicate PhiCal in order to determine performance characteristics. And to correlate Calpro levels to the gut microbiome composition.
open to eligible people ages 18-60
The purpose of this research study is to improve the understanding of irritable bowel syndrome (IBS) and its underlying cause. The investigators will use magnetic resonance imaging (MRI) to observe differences in the brain between people diagnosed with IBS compared to healthy controls and people with ulcerative colitis, a disease group that has already been characterized. By doing this correlative and comparative study, the investigators hope to gain knowledge on IBS in order to keep the field moving in the right direction and becoming one step closer to discovering effective treatments.
open to eligible people ages 18-70
This is a pilot study to determine the efficacy of the Stress Management and Resilience Training (SMART) program in improving gastrointestinal and psychological symptoms, health-related quality of life, and satisfaction of care in patients with irritable bowel syndrome (IBS). Half of the participants will be enrolled in the SMART program initially. The other half will be placed in a self-management stress reduction program where they will read a popular stress reduction book over 12 weeks. Then they will have access to participate in the online SMART program.
Sorry, accepting new patients by invitation only
The purpose of this study is to determine the amount and timing of when certain Fermentable Oligo-Di-Monosaccharides and Polyols (FODMAPs), specifically fructose, can be safely reintroduced into the diet of Irritable Bowel Syndrome (IBS) patients that have successfully completed a low-FODMAP elimination diet. The FODMAP diet is an effective treatment for IBS; however it is unclear how patients can successfully reintroduce and liberalize fructose into their diet. The low FODMAP diet is thought to reduce IBS symptoms by decreasing water content and gas production in the bowel and also possibly by altering gut bacteria. Although use of the FODMAP elimination diet can initially successfully treat IBS symptoms for up to 50-75% of patients, the reintroduction diet is difficult for patients to complete and maintain for long periods of time because current methods for reintroduction of FODMAPs are imprecise leading to frequent recurrent symptoms. As a result, patients often continue the low FODMAP elimination diet for additional months because they have difficulties knowing how to add back Protocol ID:IRB#16-000934 UCLA IRB Approved Approval Date: 2/22/2017 Through: 9/20/2017 Committee: Medical IRB 1 FODMAPs into their diet. There are no studies to date to help guide patients with FODMAP reintroduction. For example, in the case of reintroducing fructose, patients currently are currently instructed to add back honey into their diet over a 3-day period using honey in 1- 3tsp doses (equivalent roughly to 2.86-8.6 grams of fructose). However, honey is a sweetener made of both fructose and glucose and it is unclear whether recurrent IBS symptoms are related to the concentration of fructose or the concentration of fructose that is in relative excess to glucose. These types of confounding problems make it difficult to generalize dietary reintroduction. The three study groups (i.e. fructose, glucose, fructose/glucose) in this study are designed to determine if and how fructose leads to recurrent IBS symptoms during the reintroduction diet. The fructose group will help to determine whether an absolute amount of fructose will lead to IBS symptoms. Based on the principals of the diet, we hypothesize IBS patients have lower thresholds for fructose tolerance. The glucose group will serve as a control since glucose is not a FODMAP and as a result is not expected to lead to recurrent symptoms. The glucose/fructose mixture group is a cross comparison group that will determine whether the relative excess fructose concentration is an important cause of IBS symptoms. Fructose absorption in the gut is dependent on glucose intake as fructose is transported with glucose from inside the gut into the body. Current studies suggest that fructose intolerance in healthy controls is highly dependent on the ratio of excess fructose to glucose. The fructose/glucose treatment group is designed to investigate this potential relationship.
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children.
Sorry, not currently recruiting here
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating IBS-D in pediatric patients 12-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric patients with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric patients with IBS-D.